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The pharmaceutically active compound theophylline (T) was cocrystallised with the 
amides formamide (1), acetamide (2), N-methylformamide (3), N,N-dimethylformamide  
(4), benzamide (5) and pyrazinamide (6), with systems T:1, T:5 and T:6 displaying 
polymorphic behaviour. The cocrystals with formamide (T:1), acetamide (T:2) and 
benzamide (T:5), and one polymorph of the cocrystal with pyrazinamide (T:6-I), contain 
an R2(9) hydrogen bonding motif between the amide cocrystal formers and the 
HN-C-C=O moiety of the theophylline molecule (an amide-pseudo amide synthon). This 
motif was, however, absent from the other polymorph of the pyrazinamide cocrystal 
(T:6-II), and also from the N-methylformamide cocrystal (T:3) (and is not possible in the 
N,N-dimethylformamide cocrystal (T:4)). These observations are rationalised using 
hydrogen bond propensity calculations, although limitations of using such calculations 
for predicting cocrystallisation are noted. The amide-pseudo amide synthon is favoured 
when theophylline cocrystallises with both primary amides and with secondary amides 
which are locked in a cis configuration. On heating, all cocrystals were found to 
dissociate before melting due to loss of the amide, making stability to dissociation a more 
meaningful measure of cocrystal stability than melting point for these systems. On 
dissociation of the cocrystals, theophylline typically crystallises as the commonly 
observed polymorph Form II. In the case of the acetamide cocrystal (T:2), however, the 
rarely observed metastable polymorph, Form V, crystallises concomitantly with Form II 
suggesting that cocrystal dissociation on heating could be a strategy for generating novel 
polymorphic forms of compounds. 
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Introduction 
 
In recent years, cocrystallisation has emerged as a strategy for improving the solid state 
properties of compounds,1-3 and has received increasing interest in many sectors of 
chemistry including the pharmaceutical industry.4,5 Cocrystals are crystal forms where 
two or more neutral molecules are present in the unit cell,6,7 and can be prepared by a 
variety of approaches including solution crystallisation, solid state grinding, thermal 
methods, freeze-drying and slurrying.8-13  
 
An important consideration with cocrystallisation is that not every pair of molecules 
has the propensity to form a cocrystal. In fact, identifying species (coformers) which will 
cocrystallise with a given compound can sometimes be an arduous process.14 When 
screening for cocrystals, a typical first step is to consider the functional groups that are 
present in the compound of interest and to select coformers that have complementary 
groups which might be expected to form strong hydrogen bonding interactions.15 Such a 
synthon based approach can be aided by using the Cambridge Structural Database (CSD) 
to identify interactions which form robustly in known crystal structures, and systematic 
surveys of these interactions, also referred to as supramolecular synthons,16 have been 
conducted.17,18 This has been taken further through the development of a hydrogen bond 
propensity tool which calculates, on the basis of previously reported crystal structures, 
the likelihood of each of interactions between the hydrogen bond donor and acceptor 
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groups in a given molecule (or in multiple molecules), and can be used to predict whether 
two molecules will cocrystallise.19,20 Cocrystallisation has also been predicted on the 
basis of parameters such as the sizes and shapes of coformers.21  
 
While there has been much focus on understanding which compounds will form 
cocrystals, and optimum methods for preparing cocrystals, less attention has been paid to 
the equally important areas of cocrystal polymorphism and cocrystal stability.22-25 During 
early studies into the cocrystallisation of pharmaceutical compounds, it was speculated 
that cocrystals may show less of a propensity for polymorphic behaviour as they would 
be expected to have fewer unsatisfied hydrogen bonding groups.22,26 In fact, the number 
of reports of cocrystal polymorphism is similar to that for single component phases,27,28 
and any historical differences are more likely to be due to difficulties associated with 
screening for different polymorphic forms of cocrystals than to an inherent tendency for 
cocrystals to be monomorphic.13,29 Cocrystal stability is not yet well understood, but 
studies have shown that cocrystals can dissociate spontaneously on heating or through 
partial dissolution of one of the coformers.2,24,25,30-32 
 
Theophylline is a pharmaceutically active compound used as a treatment for asthma 
and COPD for which seven polymorphic forms have been reported.33-38 Over 40 
cocrystals of theophylline are present in the Cambridge Structural Database (version 
5.36, see Supporting Information Table S1), three of which comprise coformers having 
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an amide functionality (a 1:1 cocrystal of theophylline and saccharin, a 1:1 cocrystal of 
theophylline and urea, and a 2:1 cocrystal monohydrate of theophylline and 
5-fluorouracil).39-41 In each case, there is an R2(9) hydrogen bonding motif between the 
HN-C-C=O moiety of the theophylline molecule and the amide group of the coformer 
(Figure 1). This interaction, which will be referred to here as an amide-pseudo amide 
motif, has not previously been considered as a synthon in supramolecular chemistry.16 
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Figure 1. Amide-pseudo amide hydrogen bonding arrangements in the crystal structures 
of (a) a 1:1 theophylline:saccharin cocrystal (CSD ref XOBCUN39), (b) a 1:1 
theophylline:urea cocrystal (CSD ref DUXZAX40) and (c) a 2:1 
theophylline:5-fluorouracil cocrystal monohydrate (CSD ref ZAYLOA41). (d) A 
schematic of the commonly observed amide-amide synthon (graph set notation42 R2(8)). 
(e) A schematic of the amide-pseudo amide motif (graph set notation R2(9)) which is 
present in the structures shown in (a-c). 
 
In this study, the robustness of the amide-pseudo amide interaction is investigated by 
cocrystallising theophylline with a series of amides: formamide, acetamide, 
N-methylformamide, N,N-dimethylformamide (DMF), benzamide and pyrazinamide 
(Figure 2). It is noted that there is currently debate in the literature over how cocrystals 
are defined,43 which includes whether or not crystal forms containing coformers which 
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are liquid at ‘room temperature’ should be classed as cocrystals or solvates. Here, 
solvates are regarded as a sub-set of cocrystals. Polymorphism and thermal stability are 
also examined within this series of cocrystals. 
 
 
Figure 2. The molecular structures of (a) theophylline (T), (b) formamide (1), 
(c) acetamide (2), (d) N-methylformamide (3), (e) N,N-dimethylformamide (4), 
(f) benzamide (5) and (g) pyrazinamide (6). 
 
 
Experimental 
 
All chemicals were purchased from Sigma-Aldrich and used as received.  
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Cocrystals were prepared by solution crystallisation and liquid assisted grinding. 
Details are given for the theophylline:benzamide cocrystal (T:5) as an example: 
 
Form I of the theophylline:benzamide cocrystal was prepared by adding 3.0 mg of 
theophylline and 2.2 mg of benzamide (1 mole equivalent) to a solution of chloroform 
pre-saturated at ambient temperature with theophylline and benzamide and dissolving the 
solid by heating. The resulting solution was allowed to cool slowly to ambient 
temperature to induce precipitation. A single crystal suitable for XRD analysis was 
generated by this method. The cocrystal was also prepared by grinding 150 mg of 
theophylline and 107.3 mg of benzamide (1 mole equivalent) with 30 µl of ethanol for 30 
minutes at 30 Hz within a 10 cm3 metal vial containing two 7 mm diameter metal balls 
using a Retsch MM200 ball mill. 
 
Powder X-ray diffraction analysis was performed on a Philips X’Pert Diffractometer 
equipped with an X’celerator RTMS detector using CuKα radiation at a wavelength of 
1.5406 Å. Data were collected between 3 and 50° 2θ at ambient temperature using a 
collection time of 5 minutes. Powders were pressed gently on a glass slide to give a level 
surface. PXRD overlays are plotted with an arbitrary intensity scale and were generated 
using X’Pert Highscore software. Measurements at non-ambient temperature were made 
using an Anton Paar TK450 heating stage (see Supporting Information).  
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Single crystal X-ray data were collected at 180 K (unless stated) on a Nonius Kappa 
CCD diffractometer equipped with an Oxford Cryosystems cooling device using MoKα 
radiation. The theophylline:acetamide cocrystal crystal structure was collected and solved 
by the EPSRC UK National Crystallographic Service at the University of Southampton44 
on a Bruker Nonius Instrument with KappaCCD area detector (φ scans and ω scans to fill 
asymmetric unit sphere). 
 
The crystal structure of theophylline:pyrazinamide cocrystal Form II was determined 
from powder X-ray data. The powder pattern was indexed using the program 
DICVOL06.45 The crystal structure was solved by a Simulated Annealing algorithm 
implemented in the program EXPO 2014.46 Rietveld refinement47 was performed using 
the program TOPAS Academic 4.1.48 The background was modelled by a Chebyshev 
polynomial and the peak shape was modelled by a pseudo-Voigt function. Correction of 
preferred orientation by the March-Dollase49 method was applied to the (111) 
crystallographic plane. Throughout the refinement, molecules were treated as rigid 
bodies, with the exception of a flexible parameter defined to permit rotation of the amide 
group of pyrazinamide molecule. The refined crystal structure was geometry-optimised 
using the plane-wave DFT code CASTEP 8.0.50 The calculation was performed using the 
PBE51 functional with G0652 dispersion correction and norm-conserving pseudo-
potentials.53 The plane wave cutoff and k-point spacing were set to 700 eV and 0.03 Å-1, 
respectively. The unit cell parameters were fixed during the optimisation. Molecular 
geometries extracted from the optimised structure were used in the final Rietveld 
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refinement. The covalent bonds to hydrogen atoms were shortened by 0.15 Å to account 
for the displacement of electron density towards the heavy atoms.  
 
Hydrogen bond propensity calculations were performed using the Solid Form module 
available as part of Mercury v3.3 software from the Cambridge Crystallographic Data 
Centre (CCDC) with version 5.35 of the Cambridge Structural Database. The default 
options were used throughout (including functional group selection). 
 
Differential scanning calorimetry (DSC) thermograms were recorded in a nitrogen 
atmosphere using a Mettler Toledo STARe DSC822e/700 calorimeter using a heating 
rate of 10 °C.min-1. Endotherms are plotted as downward peaks. Samples were prepared 
in 40 µl aluminum pans which were sealed using a cold weld. 
 
 
Results 
 
Cocrystallisation between theophylline and formamide (T and 1), and between 
theophylline and acetamide (T and 2), was attempted experimentally by grinding (ethanol 
was added to the latter to facilitate conversion), yielding a new crystal form in each case. 
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Single crystals of these new phases suitable for X-ray structure determination were 
obtained from solution crystallisations and they were each determined to be of 1:1 
stoichiometry (T:1-I and T:2 respectively). In both structures, theophylline and amide 
molecules combine in a pairwise manner through amide-pseudo amide hydrogen bond 
dimer interactions. The dimers are themselves linked through hydrogen bonding between 
the NH2 groups of the amide and the imidazole nitrogen atoms of theophylline to give 
hydrogen bonded chains (Figure 3a-b). The chains stack in an antiparallel manner to form 
layers, which in turn close pack to give the full 3-D arrangements. The most noteworthy 
difference between the two structures is a slight corrugation of the layers in the 
theophylline:acetamide cocrystal (Figure 3c-d). 
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Figure 3. Hydrogen bonding arrangements in the crystal structures of (a) a 1:1 
theophylline:formamide cocrystal (270 K) (T:1-I) and (b) a 1:1 theophylline:acetamide 
cocrystal (T:2). (c) Crystal packing in T:1-I viewed in the direction of the hydrogen 
bonded chains of theophylline and formamide molecules. (d) An equivalent view for the 
T:2 structure. 
 
 
It is noted that the existence of a theophylline:acetamide cocrystal has previously been 
postulated by Abourahma et al on the basis of powder X-ray diffraction data.54 The full 
crystal structure of the 1:1 theophylline acetamide cocrystal reported here confirms this 
earlier observation. 
 
The fact that theophylline cocrystallises with formamide and acetamide indicates that 
theophylline-amide interactions are favoured over amide-amide and theophylline-
theophylline interactions for these pairs of molecules. In order to further probe this 
potential competition between homo and hetero interactions, cocrystallisation was 
attempted between theophylline and the bulkier amides benzamide (5) and pyrazinamide 
(6), and also with the amides N-methylformamide (3) and DMF (4), for which fewer 
theophylline-amide interactions are possible. Furthermore, pyrazinamide possesses two 
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aromatic nitrogen atoms which could potentially act as hydrogen bond acceptors. 
Cocrystallisation occurred with theophylline and each of the four amides, and the crystal 
structures were determined demonstrating a 1:1 theophylline to amide ratio in each case. 
The hydrogen bonding arrangements are shown in Figure 4. 
 
        
                 
 
Figure 4. Hydrogen bonding arrangements in the crystal structures of (a) Form I of a 
theophylline:benzamide cocrystal (T:5-I), (b) Form I of a theophylline:pyrazinamide 
cocrystal (T:6-I), (c) a theophylline:N-methylformamide cocrystal (T:3) and (d) a 
theophylline:DMF cocrystal (T:4). 
a b 
d c 
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The amide-pseudo amide hydrogen bond dimer interaction is observed in T:5-I and 
T:6-I, with NH…N hydrogen bonds bridging these dimers to give hydrogen bonded 
chains of molecules as seen for the formamide and acetamide (T:1 and T:2) cocrystals 
(though in T:6-I the hydrogen bonding no longer occurs in the same plane giving rise to a 
twisting of the chains). With both N-methylformamide (3) and DMF (4), although there is 
an interaction between the hydrogen bond donor NH group of theophylline and the amide 
carbonyl group, the full amide-pseudo amide interaction is not formed. In the case of 
DMF this is not surprising as the amide does not possess a hydrogen bond donor group. 
Interestingly, with N-methylformamide, the hydrogen bond donor NH group of the amide 
interacts with the imidazole nitrogen of a second theophylline molecule, rather than with 
theophylline’s cyclic carbonyl group, to give hydrogen bonded chains instead of the 
expected discrete dimers. This observation can be rationalised by considering the 
energies of different conformations of the N-methylformamide molecule. The cis-form, 
which would be needed in order to form an amide-pseudo amide interaction in the 
cocrystal, has been calculated to be 0.872 kcal.mol-1 higher in energy than the trans-form 
(that shown in Figure 4c),55  potentially making the formation of an amide-pseudo amide 
interaction energetically unfavourable.  
 
Cocrystal Stability 
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A further observation is that the decreasing number of theophylline-amide hydrogen 
bonds in the cocrystal series with formamide (T:1-I), N-methylformamide (T:3) and 
DMF (T:4) has a pronounced influence on cocrystal stability. Each of these cocrystals 
was found to be unstable during storage under ambient conditions due to desolvation of 
the amide, but the relative rate of desolvation was found to be DMF >> 
N-methylformamide > formamide (the DMF cocrystal dissociates completely within an 
hour, whereas the formamide cocrystal loses solvent slowly over a period of several days 
as measured by PXRD (see Supporting Information Figures S1– S2)). 
The thermal stability of the acetamide (T:2), benzamide (T:5-I) and pyrazinamide 
(T:6-I) cocrystals, which are stable under ambient conditions, was also investigated. The 
melting points of these cocrystals were determined by DSC analysis (in sealed pans) to be 
169° C, 144° C and 205° C respectively (see Supporting Information Figures S3-S5). 
Interestingly, the trend in cocrystal melting points differs from that for the individual 
amide coformers (the melting points of acetamide, benzamide and pyrazinamide were 
measured by DSC to be 80° C, 125° C and 189° C respectively – Supporting Information 
Figures S6-S8). Similar observations have been made previously for cocrystals of the 
pharmaceutical ingredient diclofenac.56 
When the three cocrystals, each prepared by grinding to give approximately equivalent 
particle sizes (as indicated by optical microscopy), were heated in an open system it was 
found that they undergo dissociation prior to melting. This dissociation is accompanied 
by sublimation of the amide coformer and crystallisation of the residual theophylline, 
typically as Form II, the most widely observed theophylline polymorph (see Supporting 
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Information Figures S9, S10 and S11). The onset of dissociation was 105° C for the 
acetamide cocrystal, 145° C for the pyrazinamide cocrystal and 165° C for the benzamide 
cocrystal (the loss of benzamide is rapid at this temperature). Importantly, the ranking of 
the cocrystals in terms of stability to thermal dissociation is different to that for melting 
temperatures, and because dissociation occurs at a lower temperature than melting it is 
perhaps the more relevant measure of thermal stability. Furthermore, the dissociation of 
the theophylline:amide cocrystals was also investigated at a constant temperature of 
80° C, a temperature relevant from a pharmaceutical perspective as it may be reached 
during processes such as drying or tableting. The relative rate of cocrystal dissociation (as 
determined by measuring the intensities of the resulting theophylline reflections) was 
found to be acetamide > benzamide > pyrazinamide, this trend being inversely related to 
the melting points of the amide coformers (i.e. the higher the melting point of the 
coformer the slower the cocrystal dissociation). 
Another noteworthy observation relating to the dissociation of the 
theophylline:acetamide cocrystal is that the loss of acetamide results in the concomitant 
crystallisation of two different polymorphic forms of theophylline, Forms II and V (see 
Supporting Information Figure S10). Form II is the most commonly observed 
theophylline polymorph, whereas Form V is a seldom observed crystal form that has been 
previously isolated during supercritical antisolvent crystallisations of theophylline,35 and 
in trace amounts during crystallisations from methanol.36 Here, thermal dissociation of 
the acetamide cocrystal has provided an alternative route to observing this unusual crystal 
form of theophylline, albeit as a minor phase in a mixture with Form II.  
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Cocrystal Polymorphism 
 
Although no extensive crystal form screening was performed during this study, second 
polymorphic forms of the formamide (T:1), benzamide (T:5) and pyrazinamide (T:6) 
cocrystals were identified while investigating the cocrystallisation of theophylline with 
these amides.  
 
The theophylline:formamide cocrystal (T:1-I) undergoes a reversible polymorphic 
conversion to a low temperature phase on cooling from room temperature to 180 K. The 
hydrogen bonding arrangement between theophylline and formamide molecules is 
maintained through this transition, enabling it to proceed in a single crystal to single 
crystal manner, but subtle changes to the crystal packing occur and give rise to a change 
of space group from P21/m to P-1. The low temperature phase will be referred to as 
Form II of the cocrystal (T:1-II). An overlay of powder X-ray diffraction patterns of 
T:1-I and T:1-II is given in the Supporting Information (Figure S12). 
 
A possible second polymorphic form of the theophylline:benzamide cocrystal (T:5-II) 
was isolated on grinding theophylline and benzamide in an equimolar ratio in the 
presence of nitromethane (as evidenced by the resulting sample having a PXRD trace that 
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was different to that of Form I of the cocrystal and to those of all of the known forms of 
theophylline and benzamide – it has not been possible to obtain a structure solution for 
this form to date and further work would be needed to unambiguously confirm that it is a 
cocrystal polymorph). Evidence that this new crystal form is a cocrystal polymorph, 
rather than a nitromethane solvate comes from the observation that grinding Form I of the 
cocrystal with nitromethane does not lead to a change in crystal form (even with several 
stoichiometric equivalents of solvent). The PXRD traces of the two polymorphs of the 
theophylline:benzamide cocrystal are shown in Figure 5. 
 
Figure 5. PXRD overlay of traces of two polymorphs of the 1:1 theophylline:benzamide 
cocrystal. (a) Experimental trace of T:5-II obtained by liquid assisted grinding with 
nitromethane. (b) Simulated trace of T:5-I. (c) Reference trace of Form II of theophylline 
Position [°2Theta]
5 10 15 20 25 30
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(simulated from CSD crystal structure BAPLOT01)33. (d) Reference trace of Form I of 
benzamide (simulated from CSD crystal structure BZAMID01). 
 
Interestingly, Form II appears to display the characteristics of a disappearing 
polymorph. This form has been obtained only twice, on both occasions through grinding 
theophylline and benzamide in the presence of nitromethane, though the same grinding 
conditions more commonly lead to the formation of Form I of the cocrystal. It is believed 
that a seeding effect has an important influence on the polymorphic outcome of the 
experiment, and if Form I of the cocrystal is present initially, even in trace amounts, this 
will direct the cocrystallisation and Form I will be obtained from the grinding. Indeed, on 
the two occasions that Form II has been isolated there had been no work on the 
theophylline:benzamide cocrystal for several months prior to the experiment, meaning 
that seeds of Form I are likely to have been absent from the laboratory. 
 
Two forms of the theophylline:pyrazinamide cocrystal were identified during this 
investigation, with the method of cocrystallisation dictating which form is obtained. 
Form I (T:6-I described above) can be generated by liquid assisted grinding in the 
presence of both polar (e.g. DMF) and non-polar (e.g. toluene) solvents. In contrast, 
solution crystallisation using both polar and non-polar solvents only yielded Form II of 
the cocrystal (T:6-II). Interestingly, in T:6-II theophylline and pyrazinamide molecules 
do not interact through amide-pseudo amide synthons, as in T:6-I, but instead form 
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homo-dimers that are linked by hydrogen bonding between the amide nitrogen atoms of 
pyrazinamide and the imidazole nitrogen atoms of theophylline to give chains (Figure 6). 
The fact that theophylline:amide dimers exist in one polymorph of the cocrystal, whereas 
theophylline:theophylline and amide:amide dimers are present in the other suggests that 
the respective hydrogen bonding arrangements are very similar in energy (experimentally 
observed polymorphs typically have lattice energies which differ by less than 10 kJ 
mol−1).57-60 
 
   
Figure 6. The crystal structure of Form II of the theophylline:pyrazinamide cocrystal 
(T:6-II). (a) Hydrogen bonding interactions between theophylline and pyrazinamide 
molecules. (b) Crystal packing in the cocrystal viewed in the direction of the hydrogen 
bonded chains of theophylline and pyrazinamide molecules. See Figure 4b for a 
comparison with Form I (T:6-I). 
 
 
a b 
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Crystallographic data for the reported theophylline:amide cocrystal structures are given 
in Table 1.  
 
 
Table 1. Crystallographic data for the reported theophylline:amide cocrystals. 
Amide coformer Formamide 
(T:1-I) 
Formamide 
(T:1-II) 
N-methylform- 
amide (T:3) 
DMF      
(T:4) 
Stoichiometry 1:1 1:1 1:1 1:1 
Crystal system Monoclinic Triclinic Triclinic Monoclinic 
Space group P21/m P-1 P-1 P21/c 
a (Å) 8.7314(3) 6.6058(13) 6.6316(3) 4.4183(1) 
b (Å) 6.6582(3) 8.7163(17) 8.7905(4) 14.3872(6) 
c (Å) 8.8996(4) 8.8843(18) 9.5955(4) 19.3622(9) 
α (degrees) 90 81.34(3) 92.441(2) 90 
β (degrees) 98.546(2) 87.63(3) 92.929(2) 93.41(3) 
γ (degrees) 90 87.47(3) 90.609(2) 90 
V (Å3) 511.64(4) 504.90(17) 558.09(4) 1228.62(8) 
Z 2 2 2 4 
λ (Å) 0.71073 0.71073 0.71073 0.71073 
θ range 3.55-27.56 3.55-27.56 3.65-30.11 3.53-26.07 
Data/constraints/ 
parameters 
1797/0/104 2267/0/149 3252/0/157 2403/0/167 
ρcalc (g.cm-3) 1.462 1.481 1.424 1.369 
T (K) 270(2) 180(2) 180(2) 250(2) 
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R1 0.0536 0.0570 0.1168 0.0545 
wR2 0.1319 0.1343 0.2978 0.1309 
 
 
 
Amide coformer Acetamide 
(T:2) 
Benzamide 
(T:5-I) 
Pyrazinamide 
(T:6-I)* 
Pyrazinamide 
(T:6-II) 
Stoichiometry 1:1 1:1 1:1 1:1 
Crystal system Triclinic Monoclinic Orthorhombic Triclinic 
Space group P-1 P21/c Pna21 P-1 
a (Å) 7.6545(13) 7.5275(2) 13.455(2) 7.4800(2) 
b (Å) 8.3489(14) 13.3891(4) 13.288(2) 7.6959(2) 
c (Å) 8.9540(16) 13.8564(4) 7.6215(4) 12.7028(4) 
α (degrees) 90.552(8) 90 90 86.113(2) 
β (degrees) 91.339(11) 91.486(2) 90 75.930(2) 
γ (degrees) 110.177(12) 90 90 68.995(2) 
V (Å3) 536.86(16) 1396.07(7) 1362.6(4) 662.02(3) 
Z 2 4 4 2 
λ (Å) 0.71073 0.71073 1.54056 0.71073 
θ range 3.12-25.00 3.95-27.11 1.5-25.0  3.75-30.03 
Data/constraints/ 
parameters 
1869/0/157 3072/0/202 -/92/37 3825/0/201 
ρcalc (g.cm-3) 1.480 1.434 1.478 1.522 
T (K) 120(2) 180(2) Ambient 180(2) 
R1 0.0909 0.0477 - 0.0548 
wR2 0.2189 0.1125 - 0.1138 
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Rwp - - 0.0660 - 
Rexp - - 0.0126 - 
 
* This structure was solved using powder X-ray diffraction data. 
 
Discussion 
The Amide-Pseudo Amide Interaction 
The R2(9) amide-pseudo amide motif is present in the formamide (both polymorphs), 
acetamide and benzamide cocrystals of theophylline, and in one of the polymorphs of the 
pyrazinamide cocrystal, but is absent from the N-methylformamide and DMF cocrystals (though 
it should be noted that there is no possibility of forming this interaction with DMF as this 
molecule has no hydrogen bond donor). From these observations it can be concluded that the 
amide-pseudo amide motif is a highly favourable interaction. On considering a wider set of 
theophylline:amide cocrystals, including both those reported here and the theophylline:amide 
cocrystals published in the CSD, it is evident that the amide-pseudo amide motif is seen with all 
of the primary amides (formamide, acetamide, benzamide, pyrazinamide and urea) and with 
secondary amides which are locked in a cis conformation, i.e. due to being part of a ring 
(saccharin and 5-fluorouracil). For other secondary amide coformers (N-methylformamide, 
paracetamol and sulfacetamide), where cocrystals with theophylline do not contain the amide-
pseudo amide motif, it appears that adopting a trans geometry gives a greater energetic 
stabilisation than forming this interaction. The exception to this trend is the 2:1 
theophylline:phenobarbital cocrystal, where, despite the cis arrangement of the amide moieties of 
2 
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the conformer, the amide-pseudo amide interaction does not occur, probably because this would 
lead to the formation of discrete trimers of molecules rather than the observed extended 
hydrogen bonded chains. 
 
Hydrogen bond propensities 
 
In order to place the above observations into the wider context of known crystal structures 
hydrogen bond propensity calculations were performed for each of the pairs of molecules 
(theophylline + amide) which were found to cocrystallise in this study. These calculations take 
into account which functional groups are involved in hydrogen bonding interactions in the 
crystal structures of similar molecules present in the CSD, and were generated using the Solid 
Form module in the Mercury v3.3 software package. For example, the hydrogen bond donor and 
acceptor groups of theophylline (T) and the amides acetamide (2), DMF (4) and 
N-methylformamide (3) are labelled in Figure 7, and the resulting propensity values for the pairs 
of molecules theophylline/formamide and theophylline/acetamide are listed in Table 2.     
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H
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NHH
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NH2
 
d1 
d2 
d3 
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a2 a3 
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Figure 7. Hydrogen bond donor and acceptor groups of the molecules theophylline (T), 
acetamide (2), DMF (4) and N-methylformamide (3) labelled with reference to the hydrogen 
bond propensities listed in Table 2. 
 
Table 2. Table showing calculated propensities for hydrogen bond formation between donor and 
acceptor groups of theophylline and the amides acetamide, DMF and N-methylformamide. The 
labelling of donor and acceptor groups is as shown in Figure 7 (T = theophylline group, A = 
amide group). Propensities are quoted on a scale from 0 to 1, with higher values indicating a 
greater likelihood of formation. 
 
Theophylline and acetamide Theophylline and DMF Theophylline and 
N-methylformamide 
Donor Acceptor Propensity Donor Acceptor Propensity Donor Acceptor Propensity 
d2 (A) a4 (A) 0.90 d1 (T) a5 (A) 0.74 d3 (A) a6 (A) 0.73 
d1 (T) a4 (A) 0.74 d1 (T) a3 (T) 0.50 d1 (T) a6 (A) 0.64 
d2 (A) a1 (T) 0.74 d1 (T) a1 (T) 0.48 d3 (A) a1 (T) 0.63 
d2 (A) a3 (T) 0.73 d1 (T) a2 (T) 0.23 d3 (A) a3 (T) 0.53 
d1 (T) a1 (T) 0.46    d1 (T) a1 (T) 0.52 
d2 (A) a2 (T) 0.44    d1 (T) a3 (T) 0.43 
d1 (T) a3 (T) 0.43    d3 (A) a2 (T) 0.31 
d1 (T) a2 (T) 0.19    d1 (T) a2 (T) 0.23 
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For the pair of molecules theophylline and acetamide, the hydrogen bond calculated to have 
the highest likelihood of formation is that between the NH2 and C=O moieties of acetamide 
(groups labelled d2 and a4 in Figure 7). Taken in isolation, this result would suggest that 
acetamide molecules are more likely to interact with each other, rather than with theophylline 
molecules, making cocrystallisation between theophylline and acetamide unlikely. When 
hydrogen bonding propensities relating to the NH donor group of theophylline (d1) are taken into 
consideration, however, it is evident that there is a much greater likelihood of this group 
interacting with the amide oxygen of acetamide (a4) than with an acceptor group from another 
theophylline molecule. In fact, the interactions that comprise an amide-pseudo amide interaction 
between theophylline and acetamide molecules (between groups d1 + a4 and d2 + a1) are 
significantly more likely to occur than any of the possible theophylline-theophylline interactions. 
This indicates there that there is competition as to whether it is the hydrogen bond donor group 
of acetamide (d2) or of theophylline (d1) that will interact with its preferred acceptor. The fact 
that theophylline and acetamide undergo cocrystallisation in practice suggests that overall 
theophylline-acetamide interactions are more favourable than the average of acetamide-
acetamide and theophylline-theophylline interactions, but it would have been difficult to predict 
with confidence ‘a priori’ whether cocrystallisation between theophylline and acetamide will 
occur without further calculations (such as determination of the relative lattice energies of 
coformers and the cocrystal through crystal structure prediction). 
 
Propensity calculations for theophylline with formamide, benzamide and pyrazinamide are 
broadly similar to those for theophylline and acetamide (see Supporting Information Table S2), 
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which is unsurprising given the identical hydrogen bonding motifs seen in the four 
corresponding cocrystal structures. 
 
As the molecule DMF does not possess a hydrogen bond donor group, the only donor for the 
theophylline/DMF system is the imidazole NH group of theophylline (d1). In the crystal 
structure, this group forms the interaction that has the highest calculated propensity, that to the 
amide oxygen of DMF (a5). 
 
With N-methylformamide, the theophylline NH hydrogen bond donor group (d1) interacts with 
its most likely acceptor, the amide carbonyl oxygen (a6). The amide NH hydrogen bond donor 
group (d3) does not, however, interact with the theophylline carbonyl group (a1) to give an 
amide-pseudo amide motif, instead forming a hydrogen bond to the imidazole nitrogen of 
theophylline (a3). The amide NH group has a similar likelihood of interacting with the carbonyl 
group and the imidazole nitrogen (0.63 and 0.53 respectively), and the fact that an interaction 
with a1 requires a higher energy cis conformation of the amide (given that the d1 – a6 interaction 
is also present) explains why the interaction with a3 is seen experimentally. 
 
Importantly, because formamide and N-methylformamide are liquids at room temperature, the 
most likely interaction, that between the NH and C=O groups of the amide (groups d2/d3 and 
a4/a6), is less relevant to a consideration of crystal forms. As theophylline-amide interactions are 
significantly more likely than theophylline-theophylline interactions, it would have been possible 
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to predict in advance that cocrystallisation would occur, as observed experimentally. 
Interestingly, when cocrystallisation between theophylline and N-methylbenzamide, an N-methyl 
substituted amide which is solid at room temperature, was attempted by liquid assisted grinding, 
no cocrystal formation occurred. Clearly, in this system there is competition between amide-
amide and theophylline-amide interactions, and it appears that the amide-amide interactions are 
dominant. 
 
Form II of the theophylline:pyrazinamide cocrystal is the only theophylline:amide cocrystal 
structure identified in this study where amide-amide hydrogen bonds, which have the highest 
calculated propensity, are actually observed. Moreover, this crystal form highlights a limitation 
of using hydrogen bond propensities to predict the likelihood that two compounds will 
cocrystallise. Even in a situation where the coformers form homosynthons, rather than 
heterosynthons, giving dimers or chains of the same molecule, there is still a possibility that 
cocrystallisation will occur if these units interact through secondary hydrogen bonds (as in the 
case of T:6-II), or favourable dispersive interactions. For this reason, other predictive tools (such 
as crystal structure prediction) will generally prove to be more robust for determining whether a 
pair of molecules will cocrystallise.  
 
Conclusions 
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The robustness of the amide-pseudo amide interaction was probed by preparing a set of 
theophylline:amide cocrystals. This motif was noted to form reliably, both with primary amides 
and secondary amides locked in a cis geometry, indicating that should be treated as a plausible 
synthon for the purposes of crystal engineering. Hydrogen bond propensity calculations were 
useful for rationalising interactions in the theophylline:amide cocrystal structures, but would not 
have given ‘a priori’ a clear indication of whether cocrystallisation would or would not occur in 
these systems. Furthermore, cocrystallisation was observed to occur in a system in which the two 
coformers did not interact through a strong hydrogen bond (theophylline:pyrazinamide, T:6-II), 
and it is noted that such a situation is not taken into account when using hydrogen bond 
propensities to predict cocrystal formation. In addition, there is an indication that it may be 
important to make a distinction between whether coformers are solid or liquid at room 
temperature when predicting the likelihood of cocrystal formation as less hydrogen bond 
competition would be expected for liquid coformers.  
 
On heating in an open system, each of the theophylline:amide cocrystals isolated in this study 
dissociated through loss of the amide coformer prior to melting. Dissociation temperature is a 
more important measure of thermal stability for these cocrystals than melting point, and it is 
likely that such a situation will be common for cocrystals in general (where one or both of the 
coformers become volatile at a temperature below the melting point of the cocrystal). 
 
Dissociation of the theophylline:acetamide cocrystal on heating yielded the rarely observed 
Form V of theophylline, demonstrating that cocrystallisation/thermal dissociation cycles could 
  
31
be a route to preparing novel or unusual metastable polymorphic forms of compounds. The 
desolvation of solvates is a widely used method of exploring polymorphism of compounds,61-63 
but to the knowledge of the authors this is the first example to demonstrate that cocrystal 
formation/thermal dissociation may provide a method of exploring polymorphism of a 
compound by giving access to alternate crystallisation conditions. 
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For table of contents use only 
An amide-pseudo amide interaction was found to be a robust synthon within a series of 
theophylline:amide cocrystals. Polymorphism and thermal stability within this cocrystal series is 
also described. 
 
